Minoxidil use in dermatology, side effects and recent patents

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 6, Issue 2, 2012, Pages 130-136

  Rossi, Alfredo ^a   Cantisani, Carmen ^a   Melis, Luca ^a   Iorio, Alessandra ^a   Scali, Elisabetta ^a   Calvieri, Stefano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Allergic contact dermatitis; Hair loss; Hair regrowth promoter; High blood pressure; Vasodilator medication

Indexed keywords

2 CYANO 1 (1,1 DIMETHYLPROPYL) 3 (3 PYRIDYL)GUANIDINE; APRIKALIM; COLLAGEN; CORTICOSTEROID; CROMAKALIM; DIAZOXIDE; MINOXIDIL; MINOXIDIL SULFATE; PINACIDIL; PROSTAGLANDIN E2; VASCULOTROPIN;

ALOPECIA; ALOPECIA AREATA; ANTIHYPERTENSIVE ACTIVITY; APPLICATION SITE REACTION; CELL GROWTH; COLLAGEN SYNTHESIS; DRUG DEGRADATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG UPTAKE; DRUG USE; DRUG WITHDRAWAL; DRY SKIN; ERYTHEMA; HAIR GROWTH; HAIR LOSS; HAIR TRANSPLANTATION; HORMONE RESPONSE; HUMAN; HYPERTRICHOSIS; HYPOTENSION; HYPOTRICHOSIS; IRRITANT DERMATITIS; MALE TYPE ALOPECIA; MONILETHRIX; MUTAGENICITY; NONHUMAN; OFF LABEL DRUG USE; PATENT; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; REVIEW; SCALP PRURITUS; SKIN ALLERGY; SKIN IRRITATION; TERATOGENICITY;

ADMINISTRATION, TOPICAL; ALOPECIA; ANIMALS; ANTIHYPERTENSIVE AGENTS; FEMALE; HAIR; HUMANS; MALE; MINOXIDIL; PATENTS AS TOPIC; POTASSIUM CHANNELS; VASODILATOR AGENTS;

EID: 84860271694     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221312800166859     Document Type: Review

References (88)

1. Dawber RPR, Rundegren J. Hypertrichosis in females applying minoxidil topical solution and in normal controls. JEADV 2003; 17: 271-275.
2. Zappacosta AR. Reversal of baldness in patient receiving minoxidil for hypertension. N Engl J Med 1980; 303: 1480-1481.
3. Walsh DS, Dunn CL, James WD. Improvement in androgenetic alopecia (stage V) using topical minoxidil in a retinoid vehicle and oral finasteride. Arch Dermatol 1995; 131: 1373-1375.
4. Buhl AE, Waldon DJ, Kawab TT, Holland JM. Minoxidil stimulates mouse vibrissae follicles in anagen culture. Invest Dermatol 1989; 92: 315-320.
5. Dooley TP, Walker CJ, Hirshey SJ, Falany CN, Diani AR. Localization of minoxidil sulfotransferase in rat liver and the outer root sheat of anagen pelage and vibrissae follicles. J Invest dermatol 1991; 96: 65-70.
6. Headington JT. Hair follicle biology and topical minoxidil: Possible mechanisms of action. Dermatologia 1987; 175(S2): 19-22.
7. De Boer EM, Besamer PD, Bruynzeel DP, Nieboer C. Does topical minoxidil increase skin blood flow? Acta derm Venereol (Stochk) 1988; 68: 271-274.
8. Wester RC, Maibach HI, Guy RH, Novak E. Minoxidil stimulates cutaneous blood flow in human balding scalp. Pharmacodynamics measured by laser Doppler velocimetry and photopulse plethys-mography. J Invest Dermatol 1984; 82: 515-517.
9. Lachgar S, Charveron M, Gall Y, Bonafe JL. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol 1998; 138: 407-411.
10. Buhl AE, Waldon DJ, Conrad SJ, Mulholland MJ, Shull KL, Kubi-cek MF, et al. Potassium channel conductance: A mechanism affecting hair growth both in vitro and in vivo. J Invest Dermatol 1992; 98: 315-319.
11. Cohen RL, Alves MEAF, Weiss VC, West DP, Chambers DA. Direct effects of minoxidil on epidermal cells in culture. J Invest Dermatol 1984; 82: 90-93.
12. Baden HP, Kubilus J. Effect of minoxidil on cultured keratinocytes. J Invest Dermatol 1983; 81: 558-560.
13. Tata S, Weiner N, Flynn G. Relative influence of ethanol and pro-pylene glycol cosolvents on deposition of minoxidil into the skin. J Pharmacol Sci 1994; 83: 1508-1510.
14. Savin RC, Atton AV. Minoxidil: Update on its clinical role. Der-matologic Therapy 1993; 11: 55-64.
15. Ferri JJ, Shepard JH, Szpunar GJ. Relationship between contact time of applied dose and percutaneous absorption of minoxidil from topical solution. J Pharm Sci 1990; 79: 483-486.
16. Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Brit J Dermatol 2004; 150: 186-194.
17. Mori O, Uno H. The effect of topical minoxidil on hair follicular cycles of rats. J Dermatol 1990; 17: 276-281.
18. Uno H, Cappas A, Brigham P. Action of topical minoxidil in the bald stump-tailed macaque. J Am Acad Dermatol 1987; 16: 657-668.
19. Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol 1999; 41: 717-721.
20. Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, et al. A randomized clinical trial of 5% topical mi-noxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002; 47: 377-385.
21. Abell E. Histologic response to topically applied minoxidil in male pattern alopecia. Clin Dermatol 1988; 6: 191-194.
22. Headington JT, Novak E. Clinical and histologic studies of male pattern baldness treated with topical minoxidil. Curr Ther Res Clin Exp 1984; 36: 1098-1106.
23. Meisheri KD, Johnson GA, Puddington L. Enzymatic and nonen zymatic sulfation mechanisms in the biological actions of minoxi-dil. Biochem Pharmacol 1993; 45: 271-279.
24. Johnson GA, Barsuhn KJ, McCall JM. Sulfation of minoxidil by liver sulfotransferase. Biochem Pharmacol 1982; 31: 2949-2954.
25. Falany CN, Kerl EA. Sulfation of minoxidil by human liver phenol sulfotransferase. Biochem Pharmacol 1990; 40: 1027-1032.
26. Johnson GA, Baker CA. Sulfation of minoxidil by human platelet sulfotransferase. Clin Chim Acta 1987; 169: 217-227.
27. Johnson GA, Baker CA, Knight KA. Minoxidil sulfotransferase, a marker of human keratinocyte differentiation. J Invest Dermatol 1992; 98: 730-733.
28. Buhl AE, Waldon DJ, Baker CA, Johnson GA. Minoxidil sulfate is the active metabolite that stimulates hair follicles. J Invest Derma-tol 1990; 95: 553-557.
29. Dooley TP, Walker CJ, Hirshey SJ, Falany CN, Diani AR. Localization of minoxidil sulfotransferase in rat liver and the outer root sheath of anagen pelage and vibrissa follicles. J Invest Dermatol 1991; 96: 65-70.
30. Hamamoto T, Mori Y. Sulfation of minoxidil in keratinocytes and hair follicles. Res Commun Chem Pathol Pharmacol 1989; 66: 33-44.
31. Baker CA, Uno H, Johnson GA. Minoxidil sulfation in the hair follicle. Skin Pharmacol 1994; 7: 335-339.
32. Dooley TP. Molecular biology of the human cytosolic sulfo transferase gene superfamily implicated in the bio activation of minoxidil and cholesterol in skin. Exp Dermatol 1999; 8: 328-329.
33. Anderson RJ, Kudlacek PE, Clemens DL. Sulfation of minoxidil by multiple human cytosolic sulfotransferases. Chem Biol Interact 1998; 109: 53-67.
34. Meisheri KD, Cipkus LA, Taylor CJ. Mechanism of action of minoxidil sulfate-induced vasodilation: A role for increased K+ permeability. J Pharmacol Exp Ther 1988; 245: 751-760.
35. Schwanstecher M, Sieverding C, Dorschner H, Gross I, Aguilar-Bryan L, Schwanstecher C, et al. Potassium channel openers require ATP to bind to and act through sulfonylurea receptors. EMBO J 1998; 17: 5529-5535.
36. + channels in pancreatic, cardiac and vascular smooth muscle cells. Am J Physiol 1998; 274: C25-C37.
37. +-channel activity in growth factor-mediated extracellular signal-regulated kinase activation in human myeloblastic leukemia ML-1 cells. Blood 1999; 94: 139-145.
38. Malhi H, Irani AN, Rajvanshi P, Suadicani SO, Spray DC, McDonald TV, et al. KATP channels regulate mitogenically induced proliferation in primary rat hepatocytes and human liver cell lines. Implications for liver growth control and potential therapeutic targeting. J Biol Chem 2000; 275: 26050-26057.
39. Koblenzer PJ, Baker L. Hypertrichosis lanuginosa associated with diazoxide therapy in prepubertal children: A clinicopathologic study. Ann N Y Acad Sci 1968; 150: 373-382.
40. Burton JL, Schutt WH, Caldwell IW. Hypertrichosis due to diazox-ide. Br J Dermatol 1975; 93: 707-711.
41. Goldberg MR. Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channels. J Cardiovasc Pharmacol 1988; 12 (Suppl 2): S41-S47.
42. Buhl AE, Conrad SJ, Waldon DJ, Brunden MN. Potassium channel conductance as a control mechanism in hair follicles. J Invest Der-matol 1993; 101: 148S-152S.
43. Harmon CS, Lutz D, Ducote J. Potassium channel openers stimulate DNA synthesis in mouse epidermal keratinocyte and whole hair follicle cultures. Skin Pharmacol 1993; 6: 170-178.
44. Imai R, Jindo T, Miura Y, Mochida K, Takamori K, Ogawa H. Organ culture of human hair follicles in serum-free medium. Arch Dermatol Res 1993; 284: 466-471.
45. Buhl AE, Kawabe TT, MacCallum DK, Waldon DJ, Knight KA, Johnson GA. Interaction of minoxidil with pigment in cells of the hair follicle: An example of binding without apparent biological effects. Skin Pharmacol 1992; 5: 114-123.
46. Boyera N, Galey I, Bernard BA. Biphasic effects of minoxidil on the proliferation and differentiation of normal human keratinocytes. Skin Pharmacol 1997; 10: 206-220
47. Murad S, Pinnell SR. Suppression of fibroblast proliferation and lysyl hydroxylase activity by minoxidil. J Biol Chem 1987; 262: 11973-11978.
48. + channel-dependent fashion. J Invest Dermatol 1996; 107: 229-234.
49. Murad S, Walker LC, Tajima S, Pinnell SR. Minimum structural requirements for minoxidil inhibition of lysyl hydroxylase in cultured fibroblasts. Arch Biochem Biophys 1994; 308: 427.
50. Kadler K, Extracellular matrix: 1. Fibril-forming collagens. Protein Profile 1994; 1: 525-534.
51. Risteli M, Niemitalo O, Lankinen H, Juffer AH, Myllyla R. Characterization of collagenous peptides bound to lysyl hydroxylase isoforms. J Biol Chem 2004; 279: 37535-37543.
52. Murad S, Pinnell SR. Suppression of fibroblast proliferation and lysyl hydroxylase activity by minoxidil. J Biol Chem 1987; 262: 11973-11978.
53. Zuurmond AM, Van der Slot-Verhoeven AMJ, Van Dura EA, De Groota J, Banka RA. Minoxidil exerts different inhibitory effects on gene expression of lysyl hydroxylase 1, 2, and 3: Implications for collagen cross-linking and treatment of fibrosis. Matrix Biology 2005; 24: 261-270.
54. Lachgar S, Charveron M, Bouhaddioui N, Neveux Y, Gall Y, Bon-afé JL. Inhibitory effects of bFGF, VEGF and minoxidil on collagen synthesis by cultured hair dermal papilla cells. Arch Dermatol Res 1996; 288: 469-473.
55. Kvedar JC, Baden HP, Levine L. Selective inhibition by minoxidil of prostacyclin production by cells in culture. Biochem Pharmacol 1988; 37: 867-874.
56. Michelet JF, Commo S, Billoni N, Mahé YF, Bernard BA. Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect. J Invest Dermatol 1997; 108: 205-209.
57. Shin H, Kwack MH, Shin SH, Oh JW, Kang BM, Kim AA, et al. Identification of transcriptional targets of Wnt/beta-catenin signaling in dermal papilla cells of human scalp hair follicles: EP2 is a novel transcriptional target of Wnt3a. J Dermatol Sci 2010; 8: 91-96.
58. Sato T, Tadokoro T, Sonoda T, Asada Y, Itami S, Takayasu S. Minoxidil increases 17 betahydroxysteroid dehydrogenase and 5 alpha-reductase activity of cultured human dermal papilla cells from balding scalp. J Dermatol Sci 1999; 19: 123-125.
59. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001; 49: 568-581.
60. Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest 2001; 107: 409-417.
61. Lachgar S, Charveron M, Gall Y, Bonafe JL. Minoxidil up regulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol 1998; 138: 407-411.
62. Wester RC, Maibach HI, Guy RH, Novak E. Minoxidil stimulates cutaneous blood flow in human balding scalps: Pharmacodynamics measured by laser Doppler velocimetry and photopulse plethys-mography. J Invest Dermatol 1984; 82: 515-517.
63. Bunker CB, Dowd PM. Alterations in scalp blood flow after the epicutaneous application of 3% minoxidil and 0.1% hexyl nicoti-nate in alopecia. Br J Dermatol 1987; 117: 668-669.
64. Sakita S, Kagoura M, Toyoda M, Morohashi M. The induction by topical minoxidil of increased fenestration in the perifollicular capillary wall. Br J Dermatol 1999; 140: 294-296.
65. Rogers NE, Avram MR. Medical treatments for male and female pattern hair loss. J Am Acad Dermatol 2008; 59(4): 547-566.
66. Olsen EA, Weiner MS, Delong ER, Pinnell SR. Topical minoxidil in early male pattern baldness. J AM Acad Dermatol 1985; 13(2 Pt 1): 185-192.
67. Avram M, Rogers N. Contemporary hair transplantation. Dermatol Surg 2009; 35(11): 1705-1719.
68. Trüeb RM. Chemotherapy-induced hair loss. Skin Therapy Lett 2010; 15(7): 5-7.
69. Garg S, Messenger AG. Alopecia areata: Evidence-based treatments. Semin Cutan Med Surg 2009; 28(1): 15-18.
70. Molina L, Donati A, Valente NS, Romiti R. Alopecia areata incognita. Clinics (Sao Paulo) 2011; 66(3): 513-515.
71. Tyagi V, Singh PK. A new approach to treating scarring alopecia by hair transplantation and topical minoxidil. Indian J Dermatol Venereol Leprol 2010; 76(2): 215.
72. Podjasek JO, Hand JL. Marie-Unna hereditary hypotrichosis: Case report and review of the literature. Pediatr Dermatol 2011; 28(2): 202-204.
73. Rossi A, Iorio A, Scali E, Fortuna MC, Mari E, Palese E, et al. Monilethrix treated with minoxidil. Int J Immunopathol Pharmacol 2011; 24(1): 239-242.
74. Jackson RV, Williamson MM, Seneviratne B, Gordon RD. Long term minoxidil therapy and renal function, cardiac function, hyper trichosis and blood pressure. Aust NZ J Med 1983; 13: 39-44.
75. Kaler SG, Patrinos ME, Lambert GH, Myers TF, Karlman R, Anderson CL. Hypertrichosis and congenital anomalies associated with maternal use of minoxidil. Pediatrics 1987; 79(3): 434-446.
76. Friedman ES, Friedman PM, Cohen DE, Washenik K. Allergic contact dermatitis to topical minoxidil solution: Etiology and treatment. J Am Acad Dermatol 2002; 46(2): 309-312.
77. Peluso AM, Misciali C, Vincenzi C, Tosti A. Diffuse hyper trichosis during treatment with 5% topical minoxidil. Br J Dermatol 1997; 136: 118-120.
78. Ingles RM, Kahn T. Unusual hair changes with minoxidil therapy. Int J Dermatol 1983; 22(2): 120-122.
79. Satoh H, Morikaw S, Fujiwara C, Terada H, Uehara A, Ohno R. A case of acute myocardial infarction associated with topical use of minoxidil (RiUP) for treatment of baldness. Jpn Heart J 2000; 41(4): 519-523.
80. Morita, R., Kanazawa, K. Minoxidil aqueous composition containing bile acid. EP2233139 (2010).
81. Padois, K., Pirot, F., Falson, F. Solid lipid nanoparticles encapsulating minoxidil, and aqueos suspension containing same. US2010112749 (2010).
82. Pena, L.E. New composition of minoxidil. US2010006829 (2010).
83. Dhuppad, U.R., Khachane, V.S., Bhamre, N.B., Pal, S.K. Topical pharmaceutical combination comprising minoxidil and aminexil. US2009101497 (2009).
84. Barranco, E.R. Pharmaceutical formula for treating skin disease. US7671044 (2010).
85. Black, K.L., Wheeler, C. Use of minoxidil sulfate as an anti-tumor drug. US7705010 (2010).
86. Maniga, N. Minoxidil composition and non-aerosol, non-spray foam method of delivery therefor. US20110189114 (2011).
87. Hu, L., Streusand, G. V., Minerva, J.A., Wendling, S. Hair growth and/or regrowth compositions. US20110144141 (2011).
88. Yee-Chien, L., Pei-Lin, W. Novel hair growth composition. US20110112125 (2011).